Comparative evaluation report: OpenAI, DeepSeek, and others demonstrate over 2x performance improvement versus previous AI models
[by Ji, Yong Jun] D&D Pharmatech announced on April (local time) that its U.S.-based subsidiary, Valted Seq, officially launched 'SCADE (Single Cell AI Discovery Engine),' an artificial intelligence (AI)-powered platform designed for the analysis of single-cell genetic big data.
Valted Seq, specializing in AI-driven single cell genetic 인터넷 바카라 사이트 for precision medicine and novel drug development, has built the world’s largest single-cell genetic database (DB), comprising tens of millions of entries, through its proprietary 인터넷 바카라 사이트 of patient brain tissue samples provided by the Johns Hopkins University School of Medicine. With the completion of the SCADE platform, the use of single-cell big data is expected to become more efficient.
SCADE enables the rapid 인터넷 바카라 사이트 of tens of millions of single-cell data, a task that was previously limited by technical constraints, thereby facilitating the identification of disease mechanisms and the discovery of novel drug targets in a remarkably short period of time. Moreover, the platform supports the development of precision 인터넷 바카라 사이트 solutions tailored to specific disease areas, including neurological disorders, cancer, and immune-related conditions.
Valted Seq has developed a standardized evaluation model that can systematically compare and assess the single-cell 인터넷 바카라 사이트 capabilities of various AI models. Using this framework, a comparative study demonstrated that SCADE achieved a 96% success rate in executing analytical codes and an accuracy rate of 36%, indicating at least a twofold improvement in performance compared to existing AI-based 인터넷 바카라 사이트 tools.
According to the company, SCADE is recognized not only for its advanced analytical performance but also for its user-friendly design. The platform is intended to offer a seamless experience for users without prior programming knowledge, enabling integrated data exploration, 인터넷 바카라 사이트, and automatic report generation all at once.
SCADE is anticipated to address the limitations of existing platforms in single-cell genetic 인터넷 바카라 사이트 and to make meaningful contributions in the future. These include the identification of disease-associated biomarkers and new drug candidates in the pharmaceutical and biotechnology industries, as well as the development of personalized treatment strategies for patients in clinical settings.
"SCADE is an innovative platform technology capable of rapidly and efficiently analyzing vast and complex genetic information," said Dr. Bardia Nezami, CEO of Valted Seq. "We are currently in discussions with a global AI company to advance the development of SCADE, aiming to enable the 인터넷 바카라 사이트 of ultra-scale big data consisting of billions of single-cell genetic profiles," he added.